Abstract: A cell culture device comprising a microscale chamber dimensioned to maintain a cell under conditions that give rise to a value for at least one pharmacokinetic parameter in vitro that is comparable to a value for the same at least one pharmacokinetic parameter obtained with respect to the same type of cell in vivo, wherein the microscale chamber is configured for flow of culture medium, and wherein the at least one pharmacokinetic parameter is selected from tissue size ratio, tissue to blood volume ratio, drug residence time, flow rate, circulatory transit time, liquid residence time, and liquid to cell ratio.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: A cell culture method using an in vitro microscale cell culture device having a first microscale chamber containing cells attached to an inner surface of the chamber and cell culture medium in contact with the cells. The cells are maintained in culture in the in vitro microscale cell culture device while flowing culture medium through the first chamber at a controlled rate to provide a liquid residence time value for the cells in the first chamber of the in vitro microscale cell culture device that is comparable to a liquid residence time value obtained with respect to comparable cells in vivo, such that metabolism by the cells in culture in the in vitro microscale cell culture device is comparable to metabolism by comparable cells in vivo.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Methods and apparatus for consolidation and visualization of a dataset output from a mass spectrometer. The number of proteins identified in a mass spectrometry experiment may be systematically reduced by identifying and excluding proteins which may not be necessary to explain the observed peptides in a sample. Peptide counts from excluded proteins may be redistributed to non-excluded proteins to preserve total observed peptide counts. The consolidated dataset may be represented as a data structure having a plurality of cells arranged into rows and columns. Visual parameter values may be assigned to various cells in the data structure to emphasize particular features of the data. Data from multiple samples may be arranged in sets of columns in the data structure, and difference scores may be calculated to determine peptide expression differences between the multiples samples. The difference scores may be displayed using textual and/or graphical representations to facilitate data analysis.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Systems and methods are disclosed for microscale pharmacokinetics. Various organs and their interactions with drug compounds can be simulated in vitro by use of microscale compartments that can be interconnected by microscale channels. Cells or cellular materials associated with the organs can be cultured in such compartments to allow interactions with drug compounds in one or more fluidic flows. Such fluidic systems can include, by way of examples, gastrointestinal flow, blood flow, bile flow, urinary flow, and brain fluid flow. Interactions between fluidic systems can be simulated by a microscale permeable member. In one example, blood-biliary interaction can be simulated by a microscale permeable material having hepatocytes bound to a permeable substrate via a binder.

Abstract: Systems and methods are disclosed for microscale pharmacokinetics. Various organs and their interactions with drug compounds can be simulated in vitro by use of microscale compartments that can be interconnected by microscale channels. Cells or cellular materials associated with the organs can be cultured in such compartments to allow interactions with drug compounds in one or more fluidic flows. Such fluidic systems can include, by way of examples, gastrointestinal flow, blood flow, bile flow, urinary flow, and brain fluid flow. Interactions between fluidic systems can be simulated by a microscale permeable member. In one example, blood-biliary interaction can be simulated by a microscale permeable material having hepatocytes bound to a permeable substrate via a binder.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.

Abstract: Devices, in vitro cell cultures, systems, and methods are provided for microscale cell culture analogous (CCA) device.